Rebecca M Brown - Neurology | Mount Sinai

Biography

Specialties

Neurology

Research Topics

Cancer

Research

Neurofibromatosis Type 1

Dr. Brown has an extensive background in laboratory research into neurofibromatosis type 1, including studying the biologic origins of cutaneous neurofibromas, and testing novel therapies in human malignant peripheral nerve sheath tumors that were xenografted into mice. In her role at Mount Sinai, she will leverage this experience into developing clinical trials to bring new treatments to patients with neurofibromatosis types 1, 2, and 3 (schwannomatosis).

Education

MD, University of Texas Southwestern Medical School

Internship, Internal Medicine, East Tennessee State University College of Medicine

Residency, Neurology, Mount Sinai Hospital

Fellowship, Neuro-oncology, Memorial Sloan-Kettering Cancer Center

Certifications

American Board of Psychiatry and Neurology

Publications

16

Publications

Selected Publications

Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis. Rebecca Brown. Current Oncology Reports

Dermatologic Manifestations of Neurofibromatosis Type 1 and Emerging Treatments. Dina Poplausky, Jade N. Young, Hansen Tai, Ryan Rivera-Oyola, Nicholas Gulati, Rebecca M. Brown. Cancers

Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. Rebeccam Brown, Sameerfarouk Sait, Griffin Dunn, Alanna Sullivan, Benjamin Bruckert, Daochun Sun. Brain Sciences

View All Publications

Office Locations

Hess CSM Building Floor 10 Room 109

1470 Madison Ave

New York, NY 10029

212-824-8579

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Brown during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

NeuroVigil, Inc
Guidepoint
Adivo Associates LLC

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Brown during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

NeuroVigil, Inc
Guidepoint
Adivo Associates LLC

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.